Guidelines for the treatment of chronic spontaneous urticaria (CSU) recommend the use of
the IgE-targeted biologic omalizumab in patients with antihistamine-refractory disease. The …

Objective Chronic urticaria (CU) is a common, heterogeneous, and debilitating disease.
Antihistamines and omalizumab are the mainstay therapies of CU. Additional treatment …

Background In the majority of patients with chronic spontaneous urticaria, most currently
available therapies do not result in complete symptom control. Ligelizumab is a next …

Importance Omalizumab is indicated for the management of chronic idiopathic urticaria
(CIU)(also known as chronic spontaneous urticaria) in adolescents and adults with …

abstract IgE and mast cells play a pivotal role in various allergic diseases, including asthma,
allergic rhinitis, and urticaria. Treatment with omalizumab, a monoclonal anti-IgE antibody …

Chronic spontaneous urticaria (CSU) is defined as the spontaneous development of itchy
hives and/or angioedema due to known or unknown causes that last for at least 6 weeks. At …

Background Many patients with chronic spontaneous urticaria (CSU) do not achieve
complete control of their symptoms with current available treatments. In a dose-finding …

Introduction: Omalizumab is a recombinant monoclonal anti-IgE antibody approved in the
US as add-on treatment in moderate-to-severe allergic asthma (in severe allergic asthma …

Allergic eosinophilic esophagitis (EoE) is a chronic, allergen-mediated inflammatory disease
of the esophagus, and the most common cause of prolonged dysphagia in children and …

Omalizumab is an effective treatment for patients with chronic spontaneous urticaria (CSU).
In routine clinical practice, physicians often face complex cases of CSU and need to decide …